A neurotoxinological approach to the treatment of obstructive sleep apnoea

Sleep Medicine Reviews

Volumn 11, Issue 5, 2007, Pages 361-375

  Conduit, Russell ^a   Sasse, Anthony ^b   Hodgson, Wayne ^c   Trinder, John ^d   Veasey, Sigrid ^e   Tucker, Adam ^f  

^a Department of Biomedical Science   (Australia)

^b Laffayette Specialist Centre   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f The Beddoes Group   (Australia)

Author keywords

Neurotoxinology; Obstructive sleep apnoea (OSA); Sleep apnoea interventions; Sleep apnoea treatment; Toxicology; Toxinology; Upper airway

Indexed keywords

BATRACHOTOXIN; BOTULINUM TOXIN A; CONOTOXIN; DELTA ATRACOTOXIN; DELTA CONOTOXIN; NEUROTOXIN; SEA ANEMONE TOXIN; SPIDER VENOM; TETANUS TOXIN; TITYUS TOXIN; UNCLASSIFIED DRUG; VERATRIDINE;

AIRWAY OBSTRUCTION; DEVICE; HUMAN; MUSCLE REFLEX; MUSCLE TONE; PATIENT COMPLIANCE; POSITIVE END EXPIRATORY PRESSURE; REVIEW; SLEEP APNEA SYNDROME; UPPER RESPIRATORY TRACT;

BATRACHOTOXINS; DRUG DELIVERY SYSTEMS; DRUG EVALUATION; HUMANS; MARINE TOXINS; MUSCLE, SKELETAL; NEUROTOXINS; RESEARCH DESIGN; SCORPION VENOMS; SLEEP; SLEEP APNEA, OBSTRUCTIVE; SNAKE VENOMS; VERATRIDINE;

EID: 34548505504     PISSN: 10870792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.smrv.2007.04.002     Document Type: Review

References (159)

1. Kuehn D.P., Folkins J.W., and Linville R.N. An electromyographic study of the musculus uvulae. Cleft Palate J 2S (1988) 348-355
2. Bosma J.F. Deglutition: pharyngeal stage. Physiol Rev 37 (1975) 275-300
3. Mathur R., Mortirnore 1.L., and Douglas N.J. Effect of breathing, pressure and posture on palatoglossal and genioglossal tone. Clin Sci 89 (1995) 441-445
4. **The most important references are denoted by an asterisk. Series F. Upper airway muscles awake and asleep. Sleep Med Rev 6 (2002) 229-242
5. *. Schwab R.J., Kuna S.T., and Remmers J.E. Anatomy and physiology of upper airway obstruction. In: Kryger M.H., Roth T., and Dement W.C. (Eds). The principles and practice of sleep medicine. 4th ed (2005), Elsevier Saunders, Pennsylvania [chapter 82]
6. *. Malhotra A., and White D.P. Obstructive sleep apnoea. Lancet 360 (2002) 237-245
7. Nolte J. The human brain: an introduction to its functional anatomy. 5th ed (2002), Mosby, St. Louis
8. Malhotra A., Pillar G., Fogel R.B., Edwards J.K., Ayas N., Akahoshi T., et al. Pharyngeal pressure and flow effects on genioglossus activation in normal subjects. Am J Respir Crit Care Med 165 1 (2002) 71-77
9. 2 rebreathing in humans. J Appl Physiol 50 5 (1981) 1052-1055
10. Malhotra A., Fogel R.B., Edwards J.K., Shea S.A., and White D.P. Local mechanisms drive genioglossus activation in obstructive sleep apnea. Am J Respir Crit Care Med 161 (2000) 1746-1749
11. Jelev A., Sood S., Liu H., Nolan P., and Horner R. Microdialysis perfusion of 5-HT into hypoglossal motor nucleus differentially modulates genioglossus activity across natural sleep-wake states in rats. J Physiol 532 (2001) 467-481
12. Lu J.W., Mann G.L., Ross R.J., Morrison A.R., and Kubin L. Differential effect of sleep-wake states on lingual and dorsal neck muscle activity in rats. Respir Physiol Neurobiol 147 (2005) 191-203
13. Fogel R.B., Trinder J., Malhotra A., Raneri J.K., Schory K., Kleverlaan D., et al. The effect of sleep onset on upper airway muscle activity in patients with sleep apnea and controls. J Physiol 564 (2005) 549-565
14. Younes M. Role of arousals in the pathogenesis of obstructive sleep apnea. AJRCCM 169 (2004) 623-633
15. Guilleminault C., and Bassiri A. Clinical features and evaluation of obstructive sleep apnea-hypopnea syndrome and upper airway resistance syndrome. In: Kryger M.H., Roth T., and Dement W.C. (Eds). The principles and practice of sleep medicine. 4th ed (2005), Elsevier Saunders, Pennsylvania [chapter 87]
16. Weaver T.E., and George C.F.P. Cognition and performance in patients with obstructive sleep apnea. In: Kryger M.H., Roth T., and Dement W.C. (Eds). The principles and practice of sleep medicine. 4th ed (2005), Elsevier Saunders, Pennsylvania [chapter 85]
17. Somers V.K., and Javaheri S. Cardiovascular effects of sleep-related breathing disorders. In: Kryger M.H., Roth T., and Dement W.C. (Eds). The principles and practice of sleep medicine. 4th ed (2005), Elsevier Saunders, Pennsylvania [chapter 99]
18. Svanborg E. Impact of obstructive apnea syndrome on upper airway respiratory muscles. Respir Physiol Neurobiol 147 (2005) 263-272
19. Horner R.L. The neuropharmacology of upper airway motor control in the awake and asleep states: implications for obstructive sleep apnoea. Respir Res 2 (2001) 286-294
20. Fogel R.B., White D.P., Pierce R.J., Malhotra A., Edwards J.K., Dunai J., et al. Control of upper airway muscle activity in younger versus older men during sleep onset. J Physiol 553 (2003) 533-544
21. Worsnop C., Kay A., Kim Y., Trinder J., and Pierce R. The effects of age on the changes in respiratory pump and upper airway muscle function during sleep onset. J Appl Physiol 88 (2000) 1831-1839
22. Worsnop C., Kay A., Pierce A.J., Kim Y., and Trinder J. The activity of respiratory pump and upper airway muscles at sleep onset. J Appl Physiol 85 (1998) 908-920
23. Okabe S., Hida W., Kikuchi Y., Taguchi O., Takishima T., and Shirato K. Upper airway muscle activity during REM and non-REM sleep of patients with obstructive apnea. Chest 106 (1994) 767-773
24. Katz E.S., and White D.P. Genioglossus activity in children with obstructive sleep apnea during wakefulness and sleep onset. Am J Respir Crit Care Med 168 (2003) 664-670
25. Katz E.S., and White D.P. Genioglossus activity during sleep in normal control subjects and children with obstructive sleep apnea. Am J Respir Crit Care Med 170 (2004) 553-560
26. Younes M. Contributions of upper airway mechanics and control mechanisms to severity of obstructive apnea. Am J Respir Crit Care Med 168 6 (2003) 645-658
27. Wiegand D.A., Latz B., Zwillich C.W., and Wiegand L. Geniohyoid muscle activity in normal men during wakefulness and sleep. J Appl Physiol 69 4 (1990) 1262-1269
28. Wiegand L., Zwillich C.W., Wiegand D., and White D.P. Changes in upper airway muscle activation and ventilation during phasic REM sleep in normal men. J Appl Physiol 71 2 (1991) 488-497
29. Shea S.A., Edwards J.K., and White D.P. Effect of wake-sleep transitions and rapid eye movement sleep on pharyngeal muscle response to negative pressure in humans. J Physiol 520 (1999) 897-908
30. Onal E., and Lopata M. Periodic breathing and the pathogenesis of occlusive sleep apneas. Am Rev Respir Dis 126 4 (1982) 676-680
31. Mezzanotte W.S., Tangel D.J., and White D.P. Waking genioglossal electromyogram in sleep apnea patients versus normal controls (a neuromuscular compensatory mechanism). J Clin Invest 89 5 (1992) 1571-1579
32. Berry R.B., White D.P., Roper J., Pillar G., Fogel R.B., Stanchina M., et al. Awake negative pressure reflex response of the genioglossus in OSA patients and normal subjects. J Appl Physiol 94 (2003) 1875-1882
33. Series F., Verin E., and Similowski T. Impediment in upper airway stabilizing forces assessed by phrenic nerve stimulation in sleep apnea patients. Respir Res 6 (2005) 99
34. Bradford A., McGuire M., and O'Halloran K.D. Does episodic hypoxia affect upper airway dilator muscle function? Implications for the pathophysiology of obstructive sleep apnoea. Respir Physiol Neurobiol 147 (2005) 223-234
35. Petrof B.J., Pack A.I., Kelly A.M., Eby J., and Hendricks J.C. Pharyngeal myopathy of loaded upper airway in dogs with sleep apnea. J Appl Physiol 76 4 (1994) 1746-1752
36. Friberg D., Gazelius B., Hokfelt T., and Nordlander B. Abnormal afferent nerve endings in the soft palatal mucosa of sleep apnoics and habitual snorers. Regul Peptides 71 1 (1997) 29-36
37. Friberg D., Ansved T., Borg K., Carlsson-Nordlander B., Larsson H., and Svanborg E. Histological indications of a progressive snorers disease in an upper airway muscle. Am J Respir Crit Care Med 157 2 (1998) 586-593
38. Edstrom L., Larsson H., and Larsson L. Neurogenic effects on the palatopharyngeal muscle in patients with obstructive sleep apnoea: a muscle biopsy study. J Neurol Neurosurg Psychiatry 55 10 (1992) 916-920
39. Lindman R., and Stal P.S. Abnormal palatopharyngeal muscle morphology in sleep-disordered breathing. J Neurol Sci 195 1 (2002) 11-23
40. Van Lunteren E., and Kaminski H.J. Disorders of sleep and breathing during sleep in neuromuscular disease. Sleep Breath 3 1 (1999) 23-30
41. Yantis M.A., and Neatherlin J. Obstructive sleep apnea in neurological patients. J Neurosci Nurs 37 3 (2005) 150-155
42. Carrera M., Barbé F., Sauleda J., Tomás M., Gómez C., and Agustí A.G.N. Patients with obstructive sleep apnea exhibit genioglossus dysfunction that is normalized after treatment with continuous positive airway pressure. Am J Respir Crit Care Med 159 (1999) 1960-1966
43. Rennie M.J., Wackerhage H., Spangenburg E.E., and Booth F.W. Control of the size of the human muscle mass. Annu Rev Physiol 66 (2004) 799-828
44. Carrera M., Barbe F., Sauleda J., Tomas M., Gomez C., Santos C., et al. Effects of obesity upon genioglossus structure and function in obstructive sleep apnoea. Eur Respir J 23 3 (2004) 425-429
45. Fry A.C. The role of resistance exercise on muscle fibre adaptations. Sports Med 34 (2004) 663-679
46. Gutmann L. Neurogenic muscle hypertrophy. Muscle Nerve 19 (1996) 811-818
47. Wheatley J.R., and White D.P. The influence of sleep on pharyngeal reflexes. Sleep 16 Suppl (1993) S87-S89
48. Wheatley J.R., Tangel D.J., Mezzanotte W.S., and White D.P. Influence of sleep on response to negative airway pressure of tensor palatini muscle and retropalatal airway. J Appl Physiol 75 5 (1993) 2117-2124
49. Wheatley J.R., Mezzanotte W.S., Tangel D.J., and White D.P. Influence of sleep on genioglossus muscle activation by negative pressure in normal men. Am Rev Respir Dis 148 3 (1993) 597-605
50. Horner R.L., Innes J.A., Morrell M.J., Shea S.A., and Guz A. The effect of sleep on reflex genioglossus muscle activation by stimuli of negative airway pressure in humans. J Physiol 476 1 (1994) 141-151
51. Suratt P.M., McTier R.F., and Wilhoit S.C. Upper airway muscle activation is augmented in patients with obstructive sleep apnea compared with that in normal subjects. Am Rev Respir Dis 137 4 (1988) 889-894
52. Carlson D.M., Onal E., Carley D.W., Lopata M., and Basner R.C. Palatal muscle electromyogram activity in obstructive sleep apnea. Am J Respir Crit Care Med 152 3 (1995) 1022-1027
53. Horner R.L., Innes J.A., Murphy K., and Guz A. Evidence for reflex upper airway dilator muscle activation by sudden negative airway pressure in man. J Physiol 436 (1991) 15-29
54. Horner R.L., Innes J.A., Morreell M.J., Shea S.A., and Guz A. The effect of sleep on reflex genioglossus muscle activation by stimuli of negative airway pressure in humans. J Physiol 476 (1994) 141-151
55. Jordan A.S., Catcheside P.G., O'Donoghue F.J., Saunders N.A., and McEvoy R.D. Genioglossus muscle activity at rest and in response to brief hypoxia in healthy men and women. J Appl Physiol 92 1 (2002) 410-417
56. Lo Y.L., Jordan A.S., Malhotra A., Wellman A., Heinzer R.C., Schory K., et al. Genioglossal muscle response to CO2 stimulation during NREM sleep. Sleep 29 4 (2006) 470-477
57. Basner R.C., Ringler J., Berkowitz S., Schwartzstein R.M., Weinberger S.E., Sparrow D., et al. Effect of inspired air temperature on genioglossus activity during nose breathing in awake humans. J Appl Physiol 69 3 (1990) 1098-1103
58. Mezzanotte W.S., Tangel D.J., and White D.P. Influence of sleep onset on upper-airway muscle activity in apnea patients versus normal controls. Am J Respir Crit Care Med 153 6 Part 1 (1996) 1880-1887
59. *. Patil S.P., Schneider H., Marx J.J., Gladmon E., Schwartz A.R., and Smith P.L. Neuromechanical control of upper airway patency during sleep. J Appl Physiol 102 2 (2007) 547-556
60. Mahamed S., Hanly P.J., Gabor J., Beecroft J., and Duffin J. Overnight changes of chemoreflex control in obstructive sleep apnoea patients. Respir Physiol Neurobiol 146 2-3 (2005) 279-290
61. Omran A.M., Aboubakr S.E., Aboussouan L.S., Pierchala L., and Badr M.S. Posthypoxic ventilatory decline during NREM sleep: influence of sleep apnea. J Appl Physiol 96 6 (2004) 2220-2225
62. Horner R.L., Shea S.A., McIvor J., and Guz A. Pharyngeal size and shape during wakefulness and sleep in patients with obstructive sleep apnoea. Q J Med 72 (1989) 719-735
63. Schwab R.J., Gupta K.B., Gefter W.B., Metzger L.J., Hoffman E.A., and Pack A.I. Upper airway and soft tissue anatomy in normal subjects and patients with sleep-disordered breathing: significance of the lateral pharyngeal walls. Am J Respir Crit Care Med 152 (1995) 1673-1689
64. Schotland H.M., Insko E.K., and Schwab R.J. Quantitative magnetic resonance imaging demonstrates alterations of the lingual musculature in obstructive sleep apnea. Sleep 22 (1999) 605-613
65. Schwab R.J., Pasirstein M., Pierson R., Mackley A., Hachadoorian R., Arens R., et al. Identification of upper airway anatomic risk factors for obstructive sleep apnea with volumetric magnetic resonance imaging. Am J Respir Crit Care Med 168 (2003) 522-530
66. Ciscar M.A., Juan G., Martinez V., Ramon M., Lloret T., Minguez J., et al. Magnetic resonance imaging of the pharynx in OSA patients and healthy subjects. Eur Respir J 17 (2001) 79-86
67. Miles P.G., Vig P.S., Weyant R.J., Forrest T.D., and Rockette Jr. H.E. Craniofacial structure and obstructive sleep apnea syndrome-a qualitative analysis and meta-analysis of the literature. Am J Orthod Dentofacial Orthop 109 (1996) 163-172
68. Gami A.S., Caples S.M., and Somers V.K. Obesity and obstructive sleep apnea. Endocrinol Metab Clin North Am 32 (2003) 869-894
69. Shelton K.E., Woodson H., Gay S.B., and Suratt P.M. Adipose tissue deposition in sleep apnea. Sleep 16 8 Suppl (1993) S103-S105
70. Shelton K.E., Woodson H., Gay S., and Suratt P.M. Pharyngeal fat in obstructive sleep apnea. Am Rev Respir Dis 148 (1993) 462-466
71. Zohar Y., Sabo R., Strauss M., Schwartz A., Gal R., and Oksenberg A. Oropharyngeal fatty infiltration in obstructive sleep apnea patients: a histologic study. Ann Otol Rhinol Laryngol 107 (1998) 170-174
72. Horner R.L., Mohiaddin R.H., Lowell D.G., Shea S.A., Burman E.D., Longmore D.B., et al. Sites and sizes of fat deposits around the pharynx in obese patients with obstructive sleep apnoea and weight matched controls. Eur Respir J 2 (1989) 613-622
73. Mortimore I.L., Marshall I., Wraith P.K., Sellar R.J., and Douglas N.J. Neck and total body fat deposition in nonobese and obese patients with sleep apnea compared with that in control subjects. Am J Respir Crit Care Med 157 1 (1998) 280-283
74. Schafer H., Pauleit D., Sudhop T., Gouni-Berthold I., Ewig S., and Berthold H.K. Body fat distribution, serum leptin, and cardiovascular risk factors in men with obstructive sleep apnea. Chest 122 3 (2002) 829-839
75. Stauffer J.L., Buick M.K., Bixler E.O., Sharkey F.E., Abt A.B., Manders E.K., et al. Morphology of the uvula in obstructive sleep apnea. Am Rev Respir Dis 140 3 (1989) 724-728
76. Series F., Cote C., Simoneau J.A., Gelinas Y., St Pierre S., Leclerc J., et al. Physiologic, metabolic, and muscle fiber type characteristics of musculus uvulae in sleep apnea hypopnea syndrome and in snorers. J Clin Invest 95 1 (1995) 20-25
77. Isono S., Remmers J.E., Tanaka A., Sho Y., Sato J., and Nishino T. Anatomy of pharynx in patients with obstructive sleep apnea and in normal subjects. J Appl Physiol 82 4 (1997) 1319-1326
78. Schwab R.J. Pro: Sleep apnea is an anatomical disorder. Am J Respir Crit Care Med 168 (2003) 270-271
79. Strohl K.P. Con: Sleep apnea is not an anatomical disorder. Am J Respir Crit Care Med 168 (2003) 271-272
80. Sullivan C.E., Issa F.G., Berthon-Jones M., and Eves L. Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares. Lancet 1 (1981) 862-865
81. Grunstein R. Continuous positive airway pressure treatment for obstructive sleep apnoea-hypopnea syndrome. In: Kryger M.H., Roth T., and Dement W.C. (Eds). The principles and practice of sleep medicine. 4th ed (2005), Elsevier Saunders, Pennsylvania [chapter 89]
82. American Thoracic Society. Indications and standards for use of nasal continuous positive airway pressure (CPAP) in sleep apnea syndromes. Am J Respir Crit Care Med 150 (1994) 1738-1745
83. *. Zozula R., and Rosen R. Compliance with continuous positive airway pressure therapy: assessing and improving treatment outcomes. Curr Opin Pulm Med 7 (2001) 391-398
84. Sher A.E., et al., The efficacy of surgical modifications of the upper-airway in adults with obstructive sleep apnea syndrome. Sleep 18 (1995) 659-666
85. *. Sundaram S., Bridgman S., Lim J., Lasserson T., and Sundaram S. Surgery for obstructive sleep apnoea. Cochrane Database Syst Rev 19 4 (2005) CD001004
86. American Sleep Disorders Association. Practice parameters for the treatment of OSA in adults: the efficacy of surgical modifications of the upper airway. Sleep 19 (1996) 152-155
87. Phillips B., and Kyger M.H. Management of obstructive sleep apnea-hypopnea syndrome: overview. In: Kryger M.H., Roth T., and Dement W.C. (Eds). The principles and practice of sleep medicine. 4th ed (2005), Elsevier Saunders, Pennsylvania [chapter 92]
88. *. Mortimore I.L., Bradley P.A., Murray J.A., and Douglas N.J. Uvulopalatopharyngoplasty may compromise nasal CPAP therapy in sleep apnea syndrome. Am J Respir Crit Care Med 154 6 Part 1 (1996) 1759-1762
89. American Sleep Disorders Association. Practice parameters for the treatment of snoring and obstructive sleep apnea with oral appliances. Sleep 18 (1995) 511-513
90. Petit F.X., et al. Mandibular advancement devices: rate of contraindictations in 100 consecutive obstructive sleep apnea patients. Am J Respir Crit Care Med 166 (2002) 274-278
91. *. Lim J., Lasserson T.J., Fleetham J., and Wright J. Oral appliances for obstructive sleep apnoea. Cochrane Database Syst Rev 18 4 (2004) CD004435
92. Ferguson K.A., and Lowe A.A. Oral appliances for sleep disordered breathing. In: Kryger M.H., Roth T., and Dement W.C. (Eds). The principles and practice of sleep medicine. 4th ed (2005), Elsevier Saunders, Pennsylvania [chapter 91]
93. Steward D.L., Weaver E.M., and Woodson B.T. A comparison of radiofrequency treatment schemes for obstructive sleep apnea syndrome. Otolaryngol Head Neck Surg 130 5 (2004) 579-585
94. Wassmuth Z., Mair E., Loube D., and Leonard D. Cautery-assisted palatal stiffening operation for the treatment of obstructive sleep apnea syndrome. Otolaryngol Head Neck Surg 123 1 Part 1 (2000) 55-60
95. Brietzke S.E., and Mair E.A. Injection snoreplasty: extended follow-up and new objective data. Otolaryngol Head Neck Surg 128 5 (2003) 605-615
96. Royal Australasian College of Surgeons. New and emerging techniques-surgical: procedure brief. Injection Snoreplasty. Australian Safety and Efficacy Register of New Intervention Procedures-Surgical, 2002. 〈http://www.surgeons.org/asernip-s_net-s/index.htm〉.
97. Hoffstein V. Apnea and snoring: state of the art and future directions. Acta Otorhinolaryngol Belg 56 (2002) 205-236
98. Guilleminault C., et al. The effect of electrical stimulation on obstructive sleep apnea syndrome. Chest 107 (1995) 67-73
99. *. Smith I., Lasserson T., and Wright J. Drug treatments for obstructive sleep apnoea. Cochrane Database Syst Rev 2 (2002) CD003002
100. Davila D.G., et al. Acute effects of transdermal nicotine on sleep architecture, snoring and sleep-disordered breathing in nonsmokers. Am J Crit Care Med 150 (1994) 469-474
101. Berry R.B., et al. Effect of theophyline on sleep and sleep-disordered breathing in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 143 (1991) 245-250
102. Hedner J., et al. A double-blind, randomized trial of sabeluzole-a putative glutamate antagonist-in obstructive sleep apnea. Sleep 19 (1996) 287-289
103. Hanzel D.A., et al. Response of OSA to fluoxetine and protriptyline. Chest 100 (1991) 416-421
104. Thorpe W.R., and Seeman P. On the mechanism of the nicotine-induced contracture of skeletal muscle. Can J Physiol Pharmacol 50 (1972) 920-923
105. Slamowitz D.I., Edwards J.K., Chajek-Shaul T., and White D.P. The influence of a transmucosal cholinergic agonist on pharyngeal muscle activity. Sleep 23 (2000) 543-550
106. Zevin S., Swed E., and Cahan C. Clinical effects of locally delivered nicotine in obstructive sleep apnea syndrome. Am J Ther 10 (2003) 170-175
107. O'Halloran K.D. Effects of nicotine on rat sternohyoid muscle contractile properties. Respir Physiol Neurobiol 150 (2006) 200-210
108. van Luteran E., Vafaie H., and Moyer M. Changes in pharyngeal respiratory muscle force produced by K+ channel blockade. Respir Physiol 105 (1996) 171-177
109. McGuire M., Cantillon D., and Bradford A. Effects of almitrine on diaphragm contractile properties in young and old rats. Respiration 69 1 (2002) 75-80
110. Smith I., Lasserson T.J., and Wright J. Drug therapy for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2 (2006) CD003002
111. Pellizzari R., et al. Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philos Trans R Soc London B 354 (1999) 259-268
112. Turton K., et al. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci 27 (2002) 552-558
113. Lacy D.B., and Stevens R.C. Sequence homology and structural analysis of the clostridial neurotoxins. J Mol Biol 291 (1999) 1091-1104
114. Simpson L.L. Botulinum neurotoxin and tetanus toxin (1989), Academic Press, San Diego
115. Montecucco C. How do tetanus and botulinum toxins bind to neural membranes?. Trends Biochem Sci 11 (1986) 314-317
116. Humeau Y., et al. How do botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 82 (2000) 427-446
117. Curtis D.R., and De Groat W.C. Tetanus toxin and spinal inhibition. Brain Res 10 (1968) 208-212
118. Mendez-Eastman S.K. BOTOX: a review. Plast Surg Nurs 20 (2000) 60-65
119. Abstracts of the international conference of basic and therapeutic aspects of Botulinum and Tetanus toxins. [Deutsche Gesellschaft fur experimentelle und klinische Pharmakologie und Toxikologie], Hannover, Germany, June 8-12. Berlin: Springer; 2002.
120. Knight A., et al. Non-viral neural gene delivery medicated by the HC fragment of tetanus toxin. Eur J Biochem 259 (1999) 762-769
121. Figueiredo D.M., et al. Delivery of recombinant tetanus-superoxide dismutase proteins to central nervous system neurons by retrograde axonal transport. Exp Neurol 145 (1997) 546-554
122. *. Sasse A., Conduit R., Ryan D., Woods W., and Tucker A.A. Pharmacotherapy for obstructve sleep apnea. Sleep 28 (2005) 1015-1016
123. Hendricks J.C., et al. The English bulldog: a natural model of sleep-disordered breathing. J Appl Physiol 63 (1987) 1344-1350
124. West P.J., Bulaj G., and Yoshikami D. Effects of delta-conotoxins PVIA and SVIE on sodium channels in the amphibian sympathetic nervous system. J Neurophysiol 94 6 (2005) 3916-3924
125. McIntosh J.M., and Jones R.M. Cone venom-from accidental stings to deliberate injection. Toxicon 39 10 (2001) 1447-1451
126. Shon K.J., Grilley M.M., Marsh M., Yoshikami D., Hall A.R., Kurz B., et al. Purification, characterization, synthesis, and cloning of the lockjaw peptide from Conus purpurascens venom. Biochemistry 34 15 (1995) 4913-4918
127. Buczek P., Buczek O., and Bulaj G. Total chemical synthesis and oxidative folding of delta-conotoxin PVIA containing an N-terminal propeptide. Biopolymers 80 1 (2005) 50-57
128. Bulaj G., DeLaCruz R., Azimi-Zonooz A., West P., Watkins M., Yoshikami D., et al. Delta-conotoxin structure/function through a cladistic analysis. Biochemistry 40 44 (2001) 13201-13208
129. + channels but not in skeletal and cardiac muscles. J Biol Chem 279 6 (2004) 4680-4685
130. Possani L.D., Merino E., Corona M., Bolivar F., and Becerril B. Peptides and genes coding for scorpion toxins that affect ion-channels. Biochimie 82 (2000) 861-868
131. +-channels. Eur J Biochem 264 (1999) 287-300
132. Zlotkin E, Miranda F, Rochat H. Chemistry and pharmacology of Buthinae scorpion venoms. In: Bettini S, editor. Handbook of experimental pharmacology, vol. 47: arthropod venoms. Berlin: Springer; 1978. p. 317-69.
133. Warnick J.E., Albuquerque E.X., and Diniz C.R. Electrophysiological observations on the action of the purified scorpion venom, tityustoxin, on nerve and skeletal muscle of the rat. J Pharmacol Exp Ther 198 (1976) 155-167
134. Senanayake N., and Roman G.C. Disorders of neuromuscular transmission due to natural environmental toxins. J Neurol Sci 107 (1992) 1-13
135. Shick J.M. A functional biology of sea anemones (1991), Chapman & Hall, London
136. Bergman C., Dubois J.M., Rojas E., and Rathmayer W. Decreased rate of sodium conductance inactivation in the node of ranvier induced by a polypeptide toxin from sea anemone. Biochim Biophys Acta 455 (1976) 173-184
137. Harris J.B., Pollard S., and Tesseraux I. The effects of Anemonia sulcata toxin II on vertebrate skeletal muscle. Br J Pharmacol (1985) 275-286
138. + channel inactivation by anemone toxin (ATX II) mimics the myotonic state in hyperkalaemic periodic paralysis. J Physiol 466 (1993) 501-520
139. Rudel R., and Lehmann-Horn F. Membrane changes in cells from myotonia patients. Physiol Rev 65 (1985) 310-356
140. Dieckman J., Prebble J., McDonogh A., Sarah A., and Fisher M.M. Efficacy of funnel web spider antivenom in human envenomation by Hadronyche species. Med J Aust 151 (1989) 706-707
141. Nicholson G.M., and Graudins A. Spiders of medicinal importance in the asia-pacific: atracotoxin, latrotoxin and related spider neurotoxins. Clin Exp Pharmacol Physiol 29 (2002) 785-794
142. Catterall W.A. Neurotoxins that act on voltage-sensitive sodium channels in excitable membranes. Annu Rev Pharmacol Toxicol 20 (1980) 15-43
143. Wang G.K., and Wang S.Y. Veratridine block of rat skeletal muscle muscle Nav1.4 sodium channels in the inner vestibule. J Physiol 548 (2003) 667-675
144. Cestele S., and Catterall W.A. Molecular mechanisms of neurotoxin action on voltage-gated sodium channels. Biochimie 82 (2000) 883-892
145. Myers C.W., and Daly J.W. Dart-poison frogs. Sci Am 248 (1983) 120-133
146. Myers C.W., Daly J.W., and Malkin B.A. Dangerously toxic new frog (Phyllobate) used by Embera Indians of Western Columbia, with discussion of blowgun fabrication and dart poisoning. Bull Am Museum Nat History 161 (1978) [Article 2]
147. Clarkson C.W., and Hondeghem L.M. Mechanism for bupivacaine depression of cardiac conduction. Anesthesiology 62 4 (1985) 396-405
148. Benzinger R.G., Tonkovich G.S., and Hanck D.A. Augmentation of recovery from inactivation by site-3 Na channel toxins: a single-channel and whole-cell study of persistent currents. J Gen Physiol 113 2 (1999) 333-346
149. Gilles N., Harrison G., Karbat I., Gurevitz M., Nicholson G.M., and Gordon D. Variations in receptor site-3 on rat brain and insect sodium channels highlighted by binding of a funnel-web spider delta-atracotoxin. Eur J Biochem 269 5 (2002) 1500-1510
150. Mylecharane E.J., Spence I., Sheumack D.D., Claassens R., and Howden M.E. Actions of robustoxin, a neurotoxic polypeptide from the venom of the male funnel-web spider (Atrax robustus), in anaesthetized monkeys. Toxicon 27 4 (1989) 481-492
151. Tuck S.A., Dort J.C., Olson M.E., and Remmers J.E. Monitoring respiratory function and sleep in the obese Vietnamese pot-bellied pig. J Appl Physiol 87 1 (1999) 444-451
152. Dixit A., Dhaked R.K., Alam S.I., and Singh L. Military potential of biological neurotoxins. Toxin Rev 24 (2005) 175-207
153. Gill D.M. Bacterial toxins: a table of lethal amounts. Microbiol Rev 46 1 (1982) 86-94
154. Mouhat S., Jouirou B., Mosbah A., De Waard M., and Sabatier J. Diversity of folds in animal toxins acting on ion channels. Biochem J 378 (2004) 717-726
155. Van de Graaff W.B., Gottfried S.B., Mitra J., van Lunteren E., Cherniack N.S., and Strohl K.P. Respiratory function of hyoid muscles and hyoid arch. J Appl Physiol 57 (1984) 197-204
156. Fregosi R.F., and Fuller D.D. Respiratory-related control of extrinsic tongue muscle activity. Respir Physiol 110 2-3 (1997) 295-306
157. *. Haniffa M., Lasserson T.J., and Smith I. Interventions to improve compliance with continuous positive airway pressure for obstructive sleep apnoea. Cochrane Database Syst Rev 18 4 (2004) CD003531
158. Smith I.E., and Quinnell T.G. Pharmacotherapies for obstructive sleep apnoea: where are we now?. Drugs 64 13 (2004) 1385-1399
159. Veasey S.C. Will we ever have an effective pharmacotherapy for obstructive sleep apnoea?. Sleep 28 (2005) 18-19